ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
Respicardia, Inc. announced today that Monument Health in Rapid City, South Dakota is the first center in the Dakotas to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.